|
GB1463520A
(en)
*
|
1974-09-06 |
1977-02-02 |
Pfizer Ltd |
Process for the production of imidazolines
|
|
JPS5373571A
(en)
*
|
1976-12-10 |
1978-06-30 |
Otsuka Pharmaceut Co Ltd |
Carbostyril derivatives
|
|
US4188393A
(en)
|
1977-04-22 |
1980-02-12 |
Sandoz Ltd. |
Treating spastic conditions or relaxing muscles
|
|
US4145421A
(en)
|
1977-04-22 |
1979-03-20 |
Sandoz Ltd. |
Treating spastic conditions
|
|
FR2449087A2
(fr)
*
|
1979-02-16 |
1980-09-12 |
Rhone Poulenc Ind |
Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
|
|
US4486432A
(en)
*
|
1982-09-30 |
1984-12-04 |
Eli Lilly And Company |
Quinoxalinedione leukotriene release inhibitors
|
|
FR2541680B1
(fr)
*
|
1983-02-24 |
1985-06-14 |
Rhone Poulenc Sante |
Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
|
|
JPS6118950U
(ja)
*
|
1984-07-10 |
1986-02-03 |
財団法人鉄道総合技術研究所 |
トロリ線の給油装置
|
|
GB8827820D0
(en)
*
|
1988-11-29 |
1988-12-29 |
Janssen Pharmaceutica Nv |
(1h-azol-1-ylmethyl)substituted quinoline derivatives
|
|
US5281591A
(en)
*
|
1989-05-22 |
1994-01-25 |
Allergan, Inc. |
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
|
|
US5180721A
(en)
*
|
1989-05-22 |
1993-01-19 |
Allergan, Inc. |
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
|
|
US5231096A
(en)
*
|
1989-10-12 |
1993-07-27 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
|
US5077292A
(en)
*
|
1989-10-12 |
1991-12-31 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
|
|
US5204347A
(en)
*
|
1989-10-12 |
1993-04-20 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
|
|
US5326763A
(en)
*
|
1989-10-12 |
1994-07-05 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
|
US5198442A
(en)
*
|
1989-10-12 |
1993-03-30 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
|
|
US5112822A
(en)
*
|
1989-10-12 |
1992-05-12 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
|
|
US5021416A
(en)
*
|
1989-10-31 |
1991-06-04 |
Allergan, Inc. |
Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
|
|
US5215991A
(en)
*
|
1990-01-26 |
1993-06-01 |
Allergan, Inc. |
Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
|
|
US5130441A
(en)
*
|
1990-02-06 |
1992-07-14 |
Allergan, Inc. |
Method for producing amino-2-imidazoline derivatives
|
|
US5237072A
(en)
*
|
1990-02-06 |
1993-08-17 |
Allergan, Inc. |
Method for producing amino-2-imidazoline derivatives
|
|
US5252595A
(en)
*
|
1990-02-28 |
1993-10-12 |
Allergan, Inc. |
Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
|
|
US5091528A
(en)
*
|
1990-09-12 |
1992-02-25 |
Allergan, Inc. |
6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
|
|
US6323204B1
(en)
*
|
1993-10-13 |
2001-11-27 |
Allergan |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
|
JP3683908B2
(ja)
*
|
1993-10-13 |
2005-08-17 |
アラーガン、インコーポレイテッド |
(2−イミダゾリン−2−イルアミノ)キノキサリン誘導体の使用方法
|
|
US5580892A
(en)
*
|
1993-10-22 |
1996-12-03 |
Allergan |
Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
|
|
US5576437A
(en)
*
|
1993-12-17 |
1996-11-19 |
The Procter & Gamble Company |
7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
|
|
FI962493A7
(fi)
*
|
1993-12-17 |
1996-07-26 |
Procter & Gamble |
Alfa-2-adrenoseptoriagonisteina käyttökelpoisia 6-(2-imidatsolinyyliam ino)kinoksaliiniyhdisteitä
|
|
US5578607A
(en)
*
|
1993-12-17 |
1996-11-26 |
The Procter & Gamble Company |
6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
|
|
DE69424183T2
(de)
*
|
1993-12-17 |
2001-02-15 |
The Procter & Gamble Company, Cincinnati |
6-(2-imidazolinylamino)chinolin-verbindungen als alpha-2-adrenoceptor-antagonisten
|
|
US5478858A
(en)
*
|
1993-12-17 |
1995-12-26 |
The Procter & Gamble Company |
5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
|
|
AU677513B2
(en)
*
|
1994-02-08 |
1997-04-24 |
Alcon Laboratories, Inc. |
Novel process for preparation of clonidine derivatives
|
|
AU704972B2
(en)
|
1994-08-04 |
1999-05-13 |
H. Lundbeck A/S |
Novel benzimidazole derivatives
|
|
US6294563B1
(en)
|
1994-10-27 |
2001-09-25 |
Allergan Sales, Inc. |
Combinations of prostaglandins and brimonidine or derivatives thereof
|
|
US6194415B1
(en)
*
|
1995-06-28 |
2001-02-27 |
Allergan Sales, Inc. |
Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
|
|
US5916900A
(en)
*
|
1995-06-29 |
1999-06-29 |
The Procter & Gamble Company |
7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
|
|
KR20000069131A
(ko)
|
1996-11-25 |
2000-11-25 |
데이비드 엠 모이어 |
알파-2 아드레날린수용체 아고니스트로서 유용한 구아니디닐 헤테로사이클 화합물
|
|
WO1998023612A1
(en)
*
|
1996-11-25 |
1998-06-04 |
The Procter & Gamble Company |
2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
|
|
HUP0002966A3
(en)
*
|
1996-11-25 |
2001-10-29 |
Procter & Gamble |
2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
|
|
US6306877B1
(en)
|
1999-08-09 |
2001-10-23 |
The Procter & Gamble Co. |
Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
|
|
US6172095B1
(en)
|
1996-11-25 |
2001-01-09 |
The Procter & Gamble Company |
Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
|
|
ES2225998T3
(es)
*
|
1996-11-25 |
2005-03-16 |
THE PROCTER & GAMBLE COMPANY |
Compuestos (2-imidazolinilamino)indol utiles como agonistas del adrenorreceptor alfa 2.
|
|
US6495583B1
(en)
|
1997-03-25 |
2002-12-17 |
Synaptic Pharmaceutical Corporation |
Benzimidazole derivatives
|
|
BR9815017A
(pt)
|
1997-11-24 |
2001-09-11 |
Procter & Gamble |
Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada
|
|
WO2004073708A1
(en)
|
1998-12-17 |
2004-09-02 |
Dean Thomas R |
Brinzolamide and brimonidine for treating ocular conditions
|
|
US20040214829A1
(en)
*
|
2000-07-14 |
2004-10-28 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
|
US20050026924A1
(en)
*
|
2000-07-14 |
2005-02-03 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
|
JP2004503593A
(ja)
|
2000-07-14 |
2004-02-05 |
アラーガン、インコーポレイテッド |
増大した溶解度を持つ治療活性成分を含む組成物
|
|
CN100569291C
(zh)
|
2000-07-14 |
2009-12-16 |
阿勒根公司 |
含有α-2肾上腺素能激动剂的组合物
|
|
US8858961B2
(en)
|
2000-07-14 |
2014-10-14 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
|
DE10161767A1
(de)
*
|
2001-12-15 |
2003-06-26 |
Merck Patent Gmbh |
2-Guanidino-4-heterocyclyl-chinazoline
|
|
US7642258B2
(en)
*
|
2002-04-19 |
2010-01-05 |
Allergan, Inc. |
Combination of brimonidine and timolol for topical ophthalmic use
|
|
US7030149B2
(en)
|
2002-04-19 |
2006-04-18 |
Allergan, Inc. |
Combination of brimonidine timolol for topical ophthalmic use
|
|
BR0314540A
(pt)
*
|
2002-10-08 |
2005-07-26 |
Allergan Inc |
Métodos para o tratamento de neurodegeneração
|
|
CA2501348A1
(en)
*
|
2002-10-08 |
2004-04-22 |
Allergan, Inc. |
Treatment of dementia and parkinson's disease
|
|
US20040191332A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Allergan, Inc. |
Preserved ophthalmic compositions
|
|
US8410102B2
(en)
|
2003-05-27 |
2013-04-02 |
Galderma Laboratories Inc. |
Methods and compositions for treating or preventing erythema
|
|
US7439241B2
(en)
|
2003-05-27 |
2008-10-21 |
Galderma Laboratories, Inc. |
Compounds, formulations, and methods for treating or preventing rosacea
|
|
DK1654002T4
(da)
|
2003-08-07 |
2014-02-17 |
Allergan Inc |
Sammensætninger til fremføring af terapeutiske midler til øjnene
|
|
US7501427B2
(en)
*
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
NZ545459A
(en)
*
|
2003-08-14 |
2009-12-24 |
Array Biopharma Inc |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
US20070042951A1
(en)
*
|
2003-10-08 |
2007-02-22 |
Allergan, Inc. |
Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
|
|
CN101426502A
(zh)
|
2004-05-25 |
2009-05-06 |
桑斯罗萨医药发展公司 |
治疗或预防炎症性皮肤疾病的化合物、制剂及方法
|
|
US7534795B2
(en)
*
|
2005-10-25 |
2009-05-19 |
Allergan, Inc. |
Compounds and their use related to compositions for treating disease
|
|
JP2009514969A
(ja)
|
2005-11-09 |
2009-04-09 |
コンビナトアールエックス インコーポレーティッド |
医学的状態を治療するための方法、組成物、およびキット
|
|
DE602006009968D1
(de)
|
2005-11-15 |
2009-12-03 |
Array Biopharma Inc |
N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
|
|
WO2008074068A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Prana Biotechnology Limited |
Substituted quinoline derivatives as antiamyloidogeneic agents
|
|
WO2008144399A1
(en)
*
|
2007-05-18 |
2008-11-27 |
Bausch & Lomb Incorporated |
COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
|
|
US7842714B2
(en)
*
|
2008-03-03 |
2010-11-30 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating ocular pain
|
|
US9192571B2
(en)
*
|
2008-03-03 |
2015-11-24 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
|
ES2756499T3
(es)
|
2009-10-06 |
2020-04-27 |
Allergan Inc |
Derivados de 2H-pirrol-5-amina como moduladores de receptor alfa adrenérgico
|
|
EP2329849B1
(en)
|
2009-11-18 |
2015-04-29 |
Galderma Research & Development |
Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
|
|
US8394800B2
(en)
|
2009-11-19 |
2013-03-12 |
Galderma Laboratories, L.P. |
Method for treating psoriasis
|
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
|
JP5747392B2
(ja)
|
2010-03-26 |
2015-07-15 |
ガルデルマ・リサーチ・アンド・デヴェロップメント |
毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
|
|
AU2011231543B2
(en)
|
2010-03-26 |
2015-01-15 |
Galderma Research & Development |
Improved methods and compositions for safe and effective treatment of erythema
|
|
WO2011127139A2
(en)
|
2010-04-07 |
2011-10-13 |
Allergan, Inc. |
Combinations of preservative compositions for ophthalmic formulations
|
|
CA2796045A1
(en)
|
2010-04-07 |
2011-10-13 |
Allergan, Inc. |
Combinations of preservatives for ophthalmic compositions
|
|
HUE040283T2
(hu)
|
2010-07-29 |
2019-02-28 |
Allergan Inc |
Brimonidin és timolol tartalmú, tartósítószer-mentes oldatok
|
|
DK2444068T4
(en)
|
2010-10-21 |
2018-03-05 |
Galderma Sa |
Brimonide sub-composition
|
|
US8053427B1
(en)
|
2010-10-21 |
2011-11-08 |
Galderma R&D SNC |
Brimonidine gel composition
|
|
JP6031719B2
(ja)
|
2011-07-25 |
2016-11-24 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
アルファ2アドレナリン作動性受容体のモジュレーターとしてのn−(イミダゾリジン−2−イリデン)キノリン誘導体
|
|
GR1009419B
(el)
|
2017-11-07 |
2018-12-14 |
Φαρματεν Αβεε |
Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
|